Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Thallion Pharmaceuticals Inc V.TLN

Healthcare Biotechnology


TSXV:TLN - Post by User

Thallion Pharmaceuticals Inc
Bullboard Posts
User Avatar Image
(0)
•••
Post by Everswanon Jun 04, 2009 3:35am
144 Views
Post# 16042420

AstraZeneca is now desperate.

AstraZeneca is now desperate.
https://www.bloomberg.com/apps/news?pid=20601085&sid=aMslTTWrojlo&refer=europe

Of course, as usual, don't believe me. Believe Bloomberg, AstraZeneca is desperate they need new pipeline drugs.

15 billions available cash, half of it for Solvay... The other half... for Thallion plenty of room for a 200-300 millions offer.

4601 could generate 1B in sale for GBM
232 skin cancer another 2B
4601 + 232 for pancreatic 1,5B

“We’re actively on the lookout for opportunities of anysize that make sense for the business and our shareholders,”spokesman Chris Sampson said in an e-mail.

There you have it.

What a twist of fortune, Thallion no longer desperate... AstraZeneca direly desperate.
What a twist of fortune

In August, Thallion Board will hold another meeting about Strategic Review...

Cheers!!!!


Can it get better?

AHAHAHAHAHHAHAHAHAHAHAHAHAHHA



Bullboard Posts
Dealroom for high-potential pre-IPO opportunities